Table 8.6a

Immunosuppression Use for Induction, 1997 to 2006

Recipients with Kidney-Pancreas Transplants

  Year of Transplant
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Transplants 853 972 941 915 891 905 871 881 903 924
With Immunosuppression Info 850 969 935 907 887 899 861 862 891 879
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 36.8% 13.4% 6.3% 3.0% 2.6% 2.8% 1.9% 2.6% 2.4% 0.7%
OKT3 42.8% 27.8% 15.5% 8.2% 3.6% 1.2% 0.3% 0.9% 0.4% 0.8%
Thymoglobulin 0.1% 0.4% 8.8% 22.9% 28.7% 39.2% 48.8% 44.3% 51.6% 62.0%
Zenapax 0.4% 20.5% 27.1% 21.8% 20.0% 16.4% 8.4% 5.0% 4.5% 5.0%
Simulect 0.4% 8.5% 17.1% 27.1% 31.1% 26.4% 16.0% 12.4% 8.2% 5.2%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 7.8% 18.6% 14.8% 11.4%
No Induction Drugs Recorded 25.5% 34.7% 33.7% 26.8% 24.4% 23.5% 20.8% 21.1% 21.2% 17.3%


Source: OPTN/SRTR Data as of May 1, 2007.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.